

1 **Title**

2 **Image-Based Quantitative Single-Cell Method Showed Increase of Global Chromatin**

3 **Accessibility in Tumor Compared to Normal Cells.**

4

5 **Authors**

6 Mairead Commane¹, Vidula Jadhav¹, Katerina Leonova¹, Brian Buckley², Henry

7 Withers^{2,3}, Katerina Gurova^{1,3}

8

9 **Affiliations**

10 ¹ – Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Elm
11 and Carlton Str, Buffalo, NY, USA, 14263.

12 ² – Drug Discovery Core Shared Resource, Roswell Park Comprehensive Cancer Center,
13 Elm and Carlton Str, Buffalo, NY, USA, 14263.

14 ³ – Department of Bioinformatics and Biostatistics, Roswell Park Comprehensive Cancer
15 Center, Elm and Carlton Str, Buffalo, NY, USA, 14263.

16

17 **Corresponding author:** Katerina Gurova, email: katerina.gurova@gmail.com

18

19 **Competing interests:** authors declare no competing financial interests in relation to the work
20 described.

21

22

23

24 **Abstract**

25 The phenotypic plasticity of cancer cells has recently emerged as an important factor of
26 treatment failure. The mechanisms of phenotypic plasticity are not fully understood. One of the
27 hypotheses is that the degree of chromatin accessibility defines the easiness of cell transitions
28 between different phenotypes. To test this, a method to compare overall chromatin accessibility
29 between cells in a population or between cell populations is needed. We propose to measure
30 chromatin accessibility by fluorescence signal from nuclei of cells stained with DNA binding
31 fluorescent molecules. This method is based on the observations that small molecules bind
32 nucleosome-free DNA more easily than nucleosomal DNA. Thus, nuclear fluorescence is
33 proportional to the amount of nucleosome-free DNA, serving as a measure of chromatin
34 accessibility. We optimized the method using several DNA intercalators and minor groove binders
35 and known chromatin-modulating agents and demonstrated that chromatin accessibility is
36 increased upon oncogene-induced transformation and further in tumor cells.

37

38

39

40 **Introduction**

41 Chromatin accessibility, or more precisely the accessibility of genomic DNA within
42 chromatin for transcriptional machinery and other protein complexes, is a crucial determinant of a
43 cell's transcriptional program and phenotype. Cells vary in their ability to change phenotype,
44 known as phenotypic plasticity, which plays a significant role in various physiological and
45 pathological processes such as differentiation, oncogenic transformation, tumor progression,
46 inflammation, etc [1]. However, we lack a reliable quantitative measure to assess and compare
47 the degree of phenotypic plasticity between different cells.

48 Theoretically, phenotypic plasticity refers to a cell's ability to switch between
49 transcriptional programs. This can be measured by observing time-dependent changes in gene
50 expression using techniques like bulk RNA-seq at different time points. While single-cell RNA
51 sequencing (scRNA-seq) is a better approach for demonstrating the heterogeneity within a cell
52 population, however it is not sufficiently quantitative. Additionally, both methods are expensive,
53 time-consuming, and require a high degree of technical expertise and sophisticated data analyses.

54 Current methods to measure chromatin accessibility as a potential proxy for phenotypic
55 plasticity are extremely laborious and not considered to be high throughput. Techniques like
56 ATAC-seq or nuclease-seq are designed to identify differences in accessibility between specific
57 genomic regions but fail to quantify altered genome-wide chromatin accessibility between cells
58 [2]. This requires the use of spike-in controls to normalize signals between different samples [3,
59 4]. The extensive biochemical and bioinformatic manipulations needed often raise questions about
60 the reliability of these comparisons.

61 Therefore, a simple and reliable method to measure general chromatin accessibility is
62 highly demanded. Extensive data indicates that the degree of chromatin condensation not only

63 defines DNA accessibility to protein complexes, such as RNA polymerases, nucleases or
64 transposases, but also to small molecules known as DNA ligands [5-8]. The two most specific
65 types of DNA ligands are DNA intercalators, heterocyclic compounds that insert their planar
66 bodies between nucleoside bases of DNA, and minor groove binders, crescent-shaped molecules
67 that position themselves inside and along the minor groove of DNA. Among both classes, there
68 are many well-known fluorescent molecules, and importantly, the fluorescent signal of many of
69 these molecules increases many folds when they are bound to DNA [9].

70 Important property of both classes of molecules, discovered long ago, is that they bind free
71 DNA more easily than DNA bound by proteins, especially histones within nucleosomes [5-8].
72 Thus, theoretically, the binding of these molecules to genomic DNA is proportional to DNA
73 accessibility, and if they fluoresce only when bound, their fluorescence could be a measure of
74 chromatin accessibility.

75 Several recent studies have proposed using DNA-binding small molecules to evaluate the
76 chromatin state in cells (see Discussion) [10-13]. Building on these previous studies, we propose
77 and optimize an approach to measure the intensity of total nuclear fluorescence of DNA-bound
78 small molecules as a reporter of chromatin accessibility in individual cells. Using several DNA
79 intercalators and minor groove binders, as well as established methods to manipulate chromatin
80 condensation, we provide evidence that the nuclear fluorescence of DNA ligands can serve as an
81 easy and quantifiable proxy for chromatin accessibility in cells and tissues. Importantly, this
82 parameter is increased in cells with higher phenotypic plasticity, such as tumor and transformed
83 cells.

84

85 **Materials and Methods**

86

87 **Reagents**

88 CBL0137 was provided by Incuron, Inc (Buffalo, NY). Propidium Iodide, RNase A, Trichostatin
89 A, Panobinostat, Valproic Acid, Vorinostat (SAHA), JQ1 were purchased from Sigma-Aldrich
90 (St. Louis, MO), DAPI, Hoechst 33342 and Sybr Green were purchased from
91 Invitrogen/ThermoFisher (Grand Island, NY). EdU kit was from Click Chemistry Tools (Scottsdale,
92 AZ).

93

94 **Cells**

95 HT1080, cells are from the American Type Culture Collection (ATCC). They were authenticated
96 using short tandem repeat analysis (100% match). MCF10A cells are from ATCC. Primary human
97 neonatal dermal fibroblasts (NDFs) were obtained from AllCells, LLC (Alameda, CA), as a pool
98 of three separate donors. HT1080 and NDF cells were maintained in high glucose DMEM
99 (Invitrogene) with 5% FBS (different vendors) and antibiotic solution in standard conditions.
100 Composition of the medium for MCF10A cells is provided in Table S1.

101

102 **Cell transformation**

103 NDF and MCF10A cells were transduced with lentivirus harboring p53 dominant negative mutant
104 GSE56 and HRasV12 oncogene connected via IRES [14]. Control cells were transduced with
105 empty virus. Cells were transduced at MOI ~ 1. After that cells were split every 3-4 days for 2
106 weeks and then taken to the experiments.

107 MEFs were isolated from C57Bl/6 p53-heterozygous bred mice. Isolated MEFs were genotyped
108 for the absence of p53, and p53-null MEFs were immortalized by stable transfection with SV40

109 large T antigen and then transformed with a vector expressing oncogenic mutant HRasV12 tagged
110 with GFP [14]. GFP positive cells were sorted flow cytometry for further experiments as a model
111 of transformed cells. To grow p53-null transformed MEFs (MEF p53KO-HRasV12) *in vivo*,
112 0.5×10^6 cells were implanted subcutaneously into wild-type C57BL/6 mice. When tumors reached
113 $500\text{-}600\text{mm}^3$, they were excised and underwent enzymatic digestion (1 mg/mL collagenase type
114 IV + 0.02 mg/mL DNase) for 1 hour at 37°C. Digested tumors were filtered through 70 μm mesh
115 filter and plated in DMEM supplemented with 10% FBS.

116

117 **Cell treatment, fixation, and staining**

118 For all imaging experiment cells were plated into 96 well black plates with clear bottom (Greiner
119 Bio-One, Monroe, NC, cat # 655090), 5000 cells per well. For flow cytometry cells were plated in
120 6 well plate at 100,000 cells per well. Next day cells were treated with CBL0137 for 10-60 min or
121 epigenetic drugs for 24 hours. After treatment medium with drugs was removed and cells were
122 fixed with 4% paraformaldehyde (PFA) in PBS with 0.1% Triton X100 or 100% ice-cold methanol
123 for 10 min at room temperature. For flow cytometry cells were first trypsinized, resuspended in
124 medium with 5% FBS, washed from medium with PBS and fixed in 4% PFA. Then fixatives were
125 removed, and cells were stained with DNA ligands with or without RNase A (100 $\mu\text{g}/\text{ml}$). Unless
126 otherwise stated, the following concentrations of DNA ligands were used Propidium Iodide (PI) –
127 1 $\mu\text{g}/\text{ml}$, DAPI and Hoechst 33342 – 1 μM , Sybr Green – 50 μM (1:100 dilution of solution
128 provided by vendor). Plate was left in staining solution overnight at room temperature to allow
129 RNA digestion.

130

131 **Image acquisition and analyses**

132 Plate imaging was done using Cytation 5 automated imager (Biotek/ Agilent Technologies, Santa
133 Clara, CA) using 4X objective in every well autofocus regimen. Each well image was montaged
134 from 4 photographs. Image processing and analysis was done using Gen5 Image Prime software
135 (Biotek/ Agilent). Data collection was done from ~300-5000 objects per well. Object masking was
136 done to include only nuclei. Before data analyses, objects from all wells were sorted by size and
137 object $<15 \mu\text{m}$ and $> 40 \mu\text{m}$ were excluded to remove cell debris or cell clusters.

138 Microscopic imaging was done using Zeiss Axio Observer A1 inverted microscope, Zeiss MRC5
139 camera, and AxioVision Rel.4.8 software.

140

141 **Statistical analyses**

142 All experiments were repeated at least twice and included at least two replicate wells. The average
143 parameter for a well was used to calculate the mean of replicate wells. For object level analyses,
144 all objects from replicate wells were pooled together. The significance of difference between
145 conditions was calculated using t-test with SciPy function `scipy.stats.ttest_ind` [15].

146

147 **Results**

148 **1. Theoretical assumptions**

149 Multiple studies have shown that DNA ligands bind preferably naked DNA versus DNA
150 wrapped around nucleosomes [5-8]. Intercalator binding through the insertion of planar
151 heterocyclic moiety requires around a 2-fold increase of inter-base pair distance [16]. Spatial and
152 superhelical constraints of nucleosomal DNA limit this binding [12]. Some histone's amino acid
153 side chains intercalate between base pairs, thus competing with DNA ligands. The minor groove
154 of DNA facing histones is inaccessible to DNA minor groove ligands. Reduced binding of DNA

155 ligands to nucleosomal versus nucleosome-free DNA was firmly established in solution and cell-
156 based experiments [5-8].

157 However, high-affinity DNA ligands compete with histones for binding of nucleosomal DNA.
158 This causes DNA unwrapping from the histone core with loss of histones from chromatin, a
159 phenomenon known as chromatin damage [17]. Therefore, such DNA ligands themselves cause
160 an increase in chromatin accessibility, which makes measuring basal chromatin accessibility
161 difficult. Another problem is that many DNA ligands are a substrate of multidrug transporters and
162 their concentration in cells depends on the activity of multi-drug transporters, which is variable
163 between cells [18]. Both these problems can be resolved by cell fixation. The most suitable seems
164 fixation with short distance crosslinking agents, since they cause covalent links between
165 molecules, effectively gluing them together into an insoluble meshwork that preserves the
166 molecular anatomy of a cell as it existed at the moment of fixation. Thus, no further nucleosome
167 unwrapping is possible.

168 The next concern is the effect of the total amount of DNA in cells, which is different between
169 G1, S, and G2 cells and may be different between healthy and diseased cells (e.g., normal and
170 tumor cells due to aneuploidy, amplifications, and deletions). Thus, cells with longer total DNA
171 would bind more DNA ligands without having more accessible chromatin. Therefore,
172 normalization for the total DNA content per cell may be needed. However, the way to measure
173 nuclear fluorescence may mitigate this issue.

174 To access overall chromatin accessibility per cell nucleus, total amount of DNA-bound dye
175 needs to be quantified, what means collection of total fluorescent signal from a nucleus. Several
176 recently published methods based on high-resolution confocal microscopy measured fluorescence
177 from a section of a cell nucleus, not of the whole nucleus. Although images can be Z-stacked, they

178 are still the sum of sections, and the total signal depends on the number and thickness of sections
179 as well as thickness of a nucleus (Fig.1A).

180 Alternative methods are flow cytometry and non-confocal microscopy. Both methods allow
181 separation of G1, S, and G2 cells, so the problem of cell cycle-dependent DNA content may be
182 easily solved by assessing the cells in the same phase of the cell cycle, e.g., G1. However, flow
183 cytometry has poor distinction between cytoplasm and nucleus (unless using special equipment
184 like ImageStream) and ligand binding to mitochondrial DNA or double-stranded RNA in
185 cytoplasm may affect the signal.

186 Automated non-confocal microscopy like flow cytometry allows collection of fluorescent
187 signals from the whole volume of a cell (Fig.1A), however, the cytoplasm and the nucleus are
188 easier separated by masking since cells are attached to the matrix. It also allows significant process
189 miniaturization: as few as several cells can be detected in multi-well plates and it does not require
190 cell detachment from a matrix on which they normally grow. It can also be applied to tissues
191 without tissue disintegration (tissue slides). We tested effects of these theoretical considerations
192 on the performance of a method in conditions of controlled chromatin decondensation in normal
193 and tumor cells.

194 **2. Optimization of an assay**

195 *2.1. Selection of a parameter of nuclear fluorescence*

196 We used normal human diploid fibroblasts NDF and human fibrosarcoma cells HT1080.
197 The latter are near diploid (modal chromosome number = 46; range = 44 to 48) [19], thus
198 eliminating the potential effect of cell aneuploidy. Cells growing in a multiwell plate were fixed
199 and stained with intercalator propidium iodide (PI) or minor groove binder DAPI. Using non-
200 confocal automatic image acquisition, we collected the following parameters: nuclear area, mean

201 – the average intensity of all pixels per nucleus, and integral – the sum of all pixel intensities per
202 nucleus. Images were collected using a 4X objective, with pixel size equal to ~1.6 microns. These
203 data are presented in the form of histograms in Figure 1B and C. As we expected, the area and the
204 integral of cells had bimodal distributions reflecting the phase of a cell cycle similar to the
205 distribution of cell fluorescence intensity measured by flow cytometry. Therefore, average integral
206 values are significantly influence by the proportion of cycling cells in a population. However, the
207 distribution of mean values did not follow the same bimodal pattern, which is explained by the
208 cell-cycle dependent increase of the nuclear size. The normalization of integral by the area of a
209 nucleus produced a distribution very similar to the mean (Fig.1B, C). Thus, we selected mean
210 nuclear fluorescence as a potential measure of chromatin accessibility in cells due to less
211 dependence on the phase of cell cycle.

212 2.2. *Comparison of DNA ligand*

213 We tested the performance of several intercalators, and minor groove binders known to be
214 highly fluorescent only when bound to nucleic acids. As an inducer of chromatin decondensation
215 we used curaxin CBL0137 which destabilizing effect on nucleosomes was shown in different
216 assays in solution and in cells [16, 20, 21]. We used a range of CBL0137 concentrations from 0.1
217 μM – no significant nucleosome unfolding, 0.3 μM – causing departure of H1 histone in some
218 cells [22], 1-3 μM - loss of outer histones H2A and H2B, and 10 μM – significant nucleosome
219 disassembly in cells ([23] and Fig. S1A). Importantly, these are approximate numbers, since these
220 effects do not happen equally genome-wide but depend on the pre-existing chromatin state and
221 cell type.

222 Cells were treated with CBL0137 for 30-60 min, since CBL0137 binds genomic DNA in cells
223 in a matter of seconds [16]. Preliminary experiments done using flow cytometry showed that a

224 shift in cell fluorescence is observed already after 10 minutes of incubation and is not significantly
225 increased anymore between 20 minutes and 1 hour (Fig. S1B and C). After treatment cells were
226 fixed and stained with Propidium Iodine (PI), Sybr Green, Hoechst 33342 or DAPI. Imaging was
227 done between 60 minutes and 24 hours with no difference between readings (data not shown).

228 The fluorescence of nuclei stained with different dyes increased with increasing doses of
229 CBL0137 (Fig. 2A, B). Though the increase in average fluorescent signal per well was very small
230 in case of minor groove binders (Fig.2A), it was highly significant when all individual cell values
231 were counted (Fig.2B). The increase was stronger with intercalators, PI and Sybr Green.

232 CBL0137-induced increase of Sybr Green fluorescence was the strongest when cells were
233 stained with 50 μ M of Sybr Green. However, when we titrated the concentration of dyes in staining
234 solution, PI fluorescent intensity decreased linearly with dye concentration, while Sybr Green
235 fluorescent intensity was bell-shaped (Fig. S2A, B). We confirmed this non-linear change in
236 fluorescence by inspection of images taken with different exposures (Fig. S2 C, D). For both
237 intercalators, the CBL0137-induced increase of fluorescent signal became smaller with increase
238 in the intensity of fluorescence in basal conditions, suggesting a saturation effect, which was
239 especially strong in the case of Sybr Green (Fig. S2E, F). With this dye automatic quantitation
240 without visual confirmation may be misleading due to easy overexposure (compare visual effect
241 and quantitation in Fig. S2 D and F).

242 2.3. *Importance of RNase A treatment*

243 Although both intercalators and minor groove binders are known as specific DNA dyes, they
244 also bind to double-stranded RNA (dsRNA). Thus, we compared the performance of all DNA dyes
245 with and without treatment of fixed cells with RNase A. Distribution of fluorescent signal was
246 changed upon RNase A treatment in all conditions (Fig. 2B – compare blue and orange halves of

247 volcano plots), however the most significant change was seen for intercalators, especially for PI
248 (Fig. 2A, B and Fig. S3). This change was explained by stronger cytoplasmic signal in cells stained
249 with intercalators in the absence of RNase A (Fig. S3). Cytoplasmic signal was gone upon RNase
250 A treatment, suggesting that intercalators stain dsRNA stronger than minor groove binders.
251 Removal of RNA staining with RNase A treatment made changes in chromatin accessibility
252 caused by CBL0137 more pronounced.

253 2.4. *The role of fixation method*

254 Although we assumed that fixation with the short-range crosslinking agent would be the
255 best, we decided to see if other fixatives, such as methanol, which causes protein denaturation can
256 be used for the same purposes. Methanol fixation led to the increase in fluorescent signal in all
257 conditions compared with PFA fixed cells (Fig. 2C). There was similar increase in DAPI and PI
258 nuclear fluorescence upon CBL0137 treatment if cells were not treated with RNase A. However,
259 RNase A treatment led to further increase of the effect of CBL0137 if cells were fixed with PFA
260 and no additional increase if cells were fixed with methanol.

261 Thus, we defined the following conditions as the most sensitive and robust for detection of
262 changes in chromatin accessibility: (i) fixation of cells with 4% PFA, (ii) treatment of cells with
263 RNase A, (iii) staining of cells with DNA intercalator dyes, with PI being less sensitive to changes
264 in dye concertation but more dependent on RNase A treatment, and Sybr Green requiring more
265 accurate concentration optimization and monitoring of exposure time, due to easy overexposure.

266

267 **3. Testing of the assay performance in cells treated with epigenetic drugs**

268 After establishing optimal conditions, we tested assay performance upon treatment of cells
269 with several epigenetic drugs with known effects on chromatin accessibility. We used HDAC

270 inhibitors, trichostatin A (TSA), panobinostat (PNB), valproic acid (VA) and vorinostat
271 (SAHA) and inhibitor of BET domain proteins, JQ1, which does not directly increase chromatin
272 accessibility. Since most of these drugs inhibit enzymes, we treated cells for 24 hours and
273 monitored the toxicity by direct cell counting and microscopic imaging (Fig. 3A, B, E, F). As
274 expected, cells treated with all HDAC inhibitors accumulated more PI than untreated cells (Fig.
275 3C-F), in line with the known mechanism of action of these agents. This effect was obvious and
276 significant even when the drug caused growth arrest (reduced number of cells per well compared
277 with control in the absence of cell death) in the case of PNB and SAHA, or cell death in the case
278 of VA (Fig. 3A, B, E, F). Interestingly, all these drugs had a stronger effect on the viability and
279 chromatin accessibility of tumor HT1080 cells, than normal NDF cells (Fig. 3). JQ1 caused the
280 minimal changes in chromatin accessibility (Fig. 3 C, D) in line with its mechanism of action.

281 Thus, our method detected chromatin accessibility changes caused by several groups of
282 epigenetic drugs though neither of these drugs bind DNA.

283

284 **4. Change of chromatin accessibility during cell cycle**

285 The amount of DNA-bound small molecules increases with DNA length. Since DNA length
286 increases with cell cycle progression populations of cells with more cycling cells would bind more
287 DNA dye due to longer average DNA length per cell. We tried to distinguish the effect of increased
288 DNA length from increased DNA accessibility by comparison of PI incorporation at different
289 phases of the cell cycle and in growth-arrested and cycling cell populations.

290 First, we identified cells in the S phase by labeling them with EdU for 1 hour and then
291 measuring the fluorescent signal of DNA ligand in cells positive and negative for EdU. This
292 comparison showed that EdU-positive cells accumulate more dye molecules, which was not

293 surprising since they have more DNA than cells in G1, the predominant state of EdU-negative
294 cells (~ 70 % of HT1080 cells in basal conditions) (Fig. 4A, B). To mitigate this factor to a certain
295 extent, we used the integral of cell fluorescence to identify cells in G1 or G2/M phases of cell cycle
296 (Fig. 4B). EdU positive cells within these groups are cells which are early in S phase and therefore
297 having DNA content close to G1 cells or very late in S phase, i.e., having DNA content close to
298 G2/M cells. When we compared mean fluorescent signal of these cells, we did not see significant
299 difference between EdU positive and negative cells (Fig. 4C, D), suggesting that DNA replication
300 per se does not make chromatin more accessible at nuclei level.

301 Another approach was to compare cells arrested with combination of contact inhibition and serum
302 starvation (48 hours in medium with 1% FBS) and normally growing cycling cells. Interestingly,
303 there was or slight decrease in basal condition and no difference upon CBL0137 treatment in the
304 dye accumulation in growing versus arrested normal NDF cells, while growing tumor HT1080
305 cells had more open chromatin. This shift was true even if we looked only at the position of G1
306 cells using the integral of fluorescence, and it was increased at high dose of CBL0137 (Fig. S4).

307 Thus, we observed more open chromatin state in cycling versus resting cells, especially in
308 the case of tumor cells and this increase cannot be explained by increased DNA length.

309

310 **5. Comparison of chromatin accessibility in normal and transformed or tumor cells**

311 Existing data from literature suggest that chromatin may be overall more open in tumor
312 than in normal cells (reviewed in [24]), though data comparing general chromatin accessibility
313 between normal, transformed and tumor cells are missing. Thus, we decided to do this using our
314 method.

315 First, we compared NDF and HT1080 cells using DAPI and PI. In both cases HT1080
316 accumulated more dye than NDF cells in basal conditions and upon CBL0137 treatment (Fig.5A,
317 B). This was true with both fixatives, PFA and methanol, and in the presence or absence of RNAse
318 A (Fig. S5A-D). Next, we compared syngeneic normal and transformed cells. NDF and
319 immortalized mammary epithelial cell line, MCF10A, were transduced with combination of p53
320 dominant negative inhibitor, GSE56 [25] and mutant HRasV12 oncogene (GR), or empty virus
321 (EV). Cells were passaged for 2 weeks to allow transformation phenotype to evolve and then they
322 were fixed and stained with DAPI. Though nuclear accumulation of this dye has been changed less
323 upon CBL0137 treatment than of PI, we observed significant difference between cells transduced
324 with empty vector and two independently generated transformed cell lines (GR1 and GR2). Both,
325 transformed fibroblasts and epithelial cells accumulated more dye than non-transformed cells (Fig.
326 5C, D), suggesting more open chromatin state in transformed versus normal cells.

327 Lastly, we compared chromatin accessibility of syngeneic mouse normal, transformed and
328 tumor cells. We used mouse embryo fibroblasts from wild type and p53 knockout animals. The
329 latter were transduced with mutant HRasV12 to get transformed cells. These transformed cells
330 were implanted subcutaneously into C57Black/6 mice and after tumor reached the size of 500
331 mm³, it was excised, disaggregated and established as cell line *in vitro*. Similar to human cells, we
332 saw increase in chromatin accessibility upon *in vitro* transformation of mouse cells and further
333 increase in tumor cells (Fig. 5E).

334 Since, as we saw in the previous section, mean fluorescence is higher in proliferating than
335 non-proliferating cells, we decided to confirm that the increase in chromatin accessibility is not
336 only due to the higher proportion of proliferating cells in transformed and tumor cell populations.
337 For this, we compared fluorescent intensities of G1 peaks obtained from the integral of

338 fluorescence. In all cases we saw shift in the position of G1 peaks corresponding to the shift of
339 mean fluorescence (Fig. 5F and S5 E-H), confirming increase in the chromatin accessibility during
340 oncogene induced transformation of human and mouse cells.

341

342 **Discussion**

343

344 The method which we described here is extremely simple and was used extensively for the
345 different purpose: to assess distribution of cells in populations along different phases of a cell cycle
346 via flow cytometry. In most cases laser settings were adjusted for every different cell type and
347 therefore shifts in the positions of histogram peaks between cell types, i.e., different fluorescent
348 intensity of different cells was largely ignored by cell and molecular biologists. At the same time
349 the fact that DNA ligands bind naked DNA better than DNA wrapped around histone core was very
350 firmly established long ago [5-8].

351 Differential accessibility of DNA in chromatin to different molecules is currently mostly
352 assessed using proteins, such as nucleases or transposases. These methods are expensive, time
353 consuming and require high level expertise in molecular biology and bioinformatics for data
354 processing. Most importantly they are not tuned for the comparison of global level of chromatin
355 accessibility between different samples.

356 Nucleosome dependent binding of small molecules to DNA in cells manifested with the
357 emission of light presents an easy opportunity to assess an abundance of nucleosome-free DNA in
358 different cells by comparing their nuclear fluorescence. This comparison can be done between cell
359 populations and between individual cells in population. Not surprisingly there were already several
360 attempts to use fluorescent DNA ligands for the assessment of chromatin organization in cells. The

361 closest approach was published by Rosevalentine Bosire et al [12]. They used different methods
362 to decondense chromatin in fixed cells to demonstrate that intercalator incorporation into nuclear
363 DNA in cells is constrained by superhelical stress due to DNA wrapping within nucleosome.
364 Unlike us, they used laser scanning cytometry, i.e. they collected the signal from a section of a
365 nucleus, and not from the whole nucleus. They observed that fluorescent signal of intercalators
366 depends on the degree of chromatin condensation and negatively correlates with the number of
367 histones per nucleus. Contrary to us they did not see the same dependence for minor groove binder
368 DAPI and when they fixed cells with methanol, probably due to assessment of a signal from one
369 section of a nucleus.

370 Differential binding of an intercalator to open and closed chromatin was used by Gali Bai et al
371 to develop a different method, adduct sequencing (Add-seq), to probe chromatin accessibility by
372 treating chromatin with the small molecule angelicin, which then was covalently bound to DNA.
373 DNA regions with bound angelicin was detected by nanopore sequencing [10]. Though in general
374 similar, this method requires nuclei isolation, DNA sequencing, and it is unclear whether it is good
375 for measurement of differences in general chromatin compaction between cells.

376 Application of DNA ligands to discern chromatin structure between tumor and normal cells
377 was proposed by Jianquan Xu et al [11]. They used minor groove binder Hoechst and stochastic
378 optical reconstruction microscopy (STORM) [26] to evaluate chromatin organization. However,
379 instead of Hoechst fluorescence, which is not optimal for super resolution, they attached another
380 fluorophore, Cy5 to Hoechst. Cy5 does not bind DNA itself but provided necessary fluorescent
381 parameters for STORM. They observed significant differences between tumor and non-tumor
382 cells, but their approach to image analysis was focused on the detection of different patterns of
383 chromatin organization and not on the total cumulative fluorescent signal from a cell [11].

384 However, their description of the observed differences was in line with the quantitative differences
385 which we observed here. They found that in normal cells chromatin domains are more compact,
386 especially at the nuclear periphery. In precancerous cells, chromatin compaction was slightly
387 disrupted, and in cancer cells chromatin at nuclear periphery was indistinguishable from the
388 interior. This can be interpreted as general chromatin de-compaction in the process of
389 tumorigenesis. This is an excellent method to detect and describe changes in the patterns of
390 chromatin organization, however, it is much more complicated in data acquisition and analysis,
391 than the method which we propose. Our method is simple enough that it can be done in a clinical
392 lab. With additional optimization it can be applied to tissue slides, and data processing can be
393 easily automated. We believe that the degree of chromatin decondensation may be an important
394 measure of tumor aggressiveness [24]. Therefore, quantitative assessment of the chromatin
395 decondensation in tumor cells and/or the proportion of cells in tumors with decondensed chromatin
396 may be used as a prognostic marker.

397 Metastasis, invasion to the neighboring organs, and development of resistance to multiple
398 therapies are factors responsible for poor prognosis of cancer patients. These traits are not often
399 due to the accumulation of new mutations and selection of resistant clones, but to the adaptation
400 of tumor cells to new conditions via changing of their phenotype, i.e., phenotypic plasticity [1, 27].
401 Although detailed mechanisms of phenotypic plasticity are still obscure, easiness of transitions
402 between transcriptional programs is probably an obligatory factor of phenotypic plasticity.
403 Transcriptional programs are controlled by chromatin organization at different genomic regions
404 and therefore stable programs should be associated with stable chromatin with multiple constraints
405 preventing easy activation and de-activation of genes. Easy transitions between active and inactive
406 state of transcription may occur when silent and active states of genomic regions are not enforced

407 strongly enough by chromatin organization, which may include unstable nucleosomes at
408 regulatory region and gene bodies leading to easier access of transcriptional machinery to DNA,
409 mobile, flexible chromatin fibers and “poorly locked” chromatin loops making random collisions
410 of promoters and enhancer more probable and burst of transcription more stochastic. Thus, our
411 long-term hypothesis was that general destabilization of chromatin through reduced number of
412 histones per cell, prevalence of histone modifications or mutations making nucleosomes less
413 stable, loss of heterochromatin proteins or overexpression of proteins making nucleosomes more
414 open, e.g., HMG proteins, these all would result in more open chromatin state in tumor versus non-
415 tumor cells. Our quantitative method confirmed this hypothesis in human and mouse models. Our
416 next hypothesis is that the degree of chromatin decondensation correlates with tumor prognosis
417 can now be tested by staining of patient’s tumor samples on slides and assessing correlation
418 between the degree of chromatin accessibility and patient outcomes. If proven correct, this may
419 become one of the simplest and universal prognostic biomarkers, which in case of development of
420 appropriate fluorescent probe can be even applied for *in vivo* imaging.

421 Although we believe that our method is simple, easy, quantitative and accurately revealing the
422 state of chromatin in cell populations and difference in chromatin condensation between individual
423 cells in a population, there are still limitations or uncertainties which need to be clarified in the
424 future studies. Ideally normalization for the total DNA length needs to be done. Better
425 understanding of the mechanisms of fluorescence as a result of interactions of molecules of DNA
426 ligand between themselves and with DNA is needed to understand which signals report accessible
427 chromatin and which is influenced by ligand-ligand interactions, as we see in the case of Sybr
428 Green. Another question is which DNA ligand better reflects actual chromatin state in different
429 conditions, minor groove binders or DNA intercalators. There is very limited data to understand

430 which properties of nucleosomal DNA define these molecules binding. Most probably their
431 binding would inform us about different complementary properties of nucleosomes. which can be
432 put together to better understand chromatin organization and dynamics. Although fluorescent
433 signal from the same cells in different experiments was in the same range, there were some
434 differences between experiments and between wells in the same experiments. For comparison of
435 different samples, especially in clinical conditions a set of controls for normalization of staining
436 and imaging and calibration of signal need to be developed.

437

438

439 **Acknowledgments**

440 We would like to acknowledge Dr. Razvan Chereji for helping with Fig. S1A
441 presentation, Drs. Andrei Gudkov and Subhamoy Dasgupta for the critical discussion of
442 the manuscript, Bruce Specht, Mary Morgan, Sarah Mercy and Dale Henry for the
443 administrative support.

444

445 **Funding:**

446 National Institutes of Health grant R01 CA266216 (KG)

447 National Institute of Health grant NCI NIH Core P30CA16056 to RPCCC, which
448 partially covers the costs Genomics, Bioinformatics, Flow Cytometry, Drug Discovery

449 Lab, Gene Modulation

450

451 **Author contributions:**

452 MC and VJ were responsible for running imaging and flow cytometry experiments. KL
453 generated mouse transformed and tumor cells. BB did imaging and image analyses, HW
454 performed analysis of some data, generated R script to define x-value of positions of G1
455 and G2 peaks on a histogram and editing of the manuscript. KG conceptualized the study,
456 analyzed all data, wrote the manuscript and prepared all figure.

457 **Competing interests:** Authors declare that they have no competing interests.

458 **Data and materials availability:** Transformed or tumor cells generated for this study are
459 available upon request. Raw imaging data are available upon request. R script to define x-
460 value of positions of G1 and G2 peaks on a histogram is available here:

461 <https://github.com/HGWithers/cellphaseR>

462

463

464 **References**

- 465 1 Gupta PB, Pastushenko I, Skibinski A, Blanpain C, Kuperwasser C. Phenotypic
466 Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance. *Cell Stem*
467 *Cell* 2019; 24: 65-78.
468
- 469 2 Minnoye L, Marinov GK, Krausgruber T, Pan L, Marand AP, Secchia S *et al.* Chromatin
470 accessibility profiling methods. *Nat Rev Methods Primers* 2021; 1.
471
- 472 3 Chen K, Hu Z, Xia Z, Zhao D, Li W, Tyler JK. The Overlooked Fact: Fundamental Need
473 for Spike-In Control for Virtually All Genome-Wide Analyses. *Mol Cell Biol* 2015; 36:
474 662-667.
475
- 476 4 Chereji RV, Bryson TD, Henikoff S. Quantitative MNase-seq accurately maps
477 nucleosome occupancy levels. *Genome Biol* 2019; 20: 198.
478
- 479 5 Giangare MC, Prosperi E, Pedrali-Noy G, Bottiroli G. Flow cytometric evaluation of
480 DNA stainability with propidium iodide after histone H1 extraction. *Cytometry* 1989; 10:
481 726-730.
482
- 483 6 Gabbay EJ, Wilson WD. Intercalating agents as probes of chromatin structure. *Methods*
484 *Cell Biol* 1978; 18: 351-384.

- 485
486 7 Lurquin PF. The use of intercalating dye molecules in the study of chromatin structure.
487 *Chem Biol Interact* 1974; 8: 303-312.
488
- 489 8 Lawrence JJ, Louis M. Ethidium bromide as a probe of chromatin structure. *FEBS Lett*
490 1974; 40: 9-12.
491
- 492 9 Bag S, Bhowmik S. Fluorescence Spectroscopy: A Useful Method to Explore the
493 Interactions of Small Molecule Ligands with DNA Structures. *Methods Mol Biol* 2024;
494 2719: 33-49.
495
- 496 10 Bai G, Dhillon N, Felton C, Meissner B, Saint-John B, Shelansky R *et al.* Probing
497 chromatin accessibility with small molecule DNA intercalation and nanopore sequencing.
498 *bioRxiv* 2024.
499
- 500 11 Xu J, Sun X, Kim K, Brand RM, Hartman D, Ma H *et al.* Ultrastructural visualization of
501 chromatin in cancer pathogenesis using a simple small-molecule fluorescent probe. *Sci*
502 *Adv* 2022; 8: eabm8293.
503
- 504 12 Bosire R, Nanasi P, Jr., Imre L, Dienes B, Szoor A, Mazlo A *et al.* Intercalation of small
505 molecules into DNA in chromatin is primarily controlled by superhelical constraint. *PLoS*
506 *One* 2019; 14: e0224936.
507
- 508 13 Imai R, Nozaki T, Tani T, Kaizu K, Hibino K, Ide S *et al.* Density imaging of
509 heterochromatin in live cells using orientation-independent-DIC microscopy. *Mol Biol*
510 *Cell* 2017; 28: 3349-3359.
511
- 512 14 Boiko AD, Porteous S, Razorenova OV, Krivokrysenko VI, Williams BR, Gudkov AV.
513 A systematic search for downstream mediators of tumor suppressor function of p53
514 reveals a major role of BTG2 in suppression of Ras-induced transformation. *Genes Dev*
515 2006; 20: 236-252.
516
- 517 15 Virtanen P, Gommers R, Oliphant TE, Haberland M, Reddy T, Cournapeau D *et al.*
518 SciPy 1.0: fundamental algorithms for scientific computing in Python. *Nat Methods*
519 2020; 17: 261-272.
520
- 521 16 Safina A, Cheney P, Pal M, Brodsky L, Ivanov A, Kirsanov K *et al.* FACT is a sensor of
522 DNA torsional stress in eukaryotic cells. *Nucleic Acids Res* 2017; 45: 1925-1945.
523
- 524 17 Neefjes J, Gurova K, Sarthy J, Szabo G, Henikoff S. Chromatin as an old and new
525 anticancer target. *Trends Cancer* 2024.
526
- 527 18 Szabo E, Kulin A, Jezso B, Kucsma N, Sarkadi B, Varady G. Selective Fluorescent
528 Probes for High-Throughput Functional Diagnostics of the Human Multidrug Transporter
529 P-Glycoprotein (ABCB1). *Int J Mol Sci* 2022; 23.
530

- 531 19 Chen TR, Hay RJ, Macy ML. Intercellular karyotypic similarity in near-diploid cell lines
532 of human tumor origins. *Cancer Genet Cytogenet* 1983; 10: 351-362.
533
- 534 20 Chang HW, Nizovtseva EV, Razin SV, Formosa T, Gurova KV, Studitsky VM. Histone
535 Chaperone FACT and Curaxins: Effects on Genome Structure and Function. *J Cancer*
536 *Metastasis Treat* 2019; 5.
537
- 538 21 Gasparian AV, Burkhart CA, Purmal AA, Brodsky L, Pal M, Saranadasa M *et al.*
539 Curaxins: anticancer compounds that simultaneously suppress NF-kappaB and activate
540 p53 by targeting FACT. *Sci Transl Med* 2011; 3: 95ra74.
541
- 542 22 Leonova K, Safina A, Neshher E, Sandlesh P, Pratt R, Burkhart C *et al.* TRAIN
543 (Transcription of Repeats Activates INterferon) in response to chromatin destabilization
544 induced by small molecules in mammalian cells. *Elife* 2018; 7.
545
- 546 23 Neshher E, Safina A, Aljahdali I, Portwood S, Wang ES, Koman I *et al.* Role of chromatin
547 damage and chromatin trapping of FACT in mediating the anticancer cytotoxicity of
548 DNA-binding small molecule drugs. *Cancer Res* 2018.
549
- 550 24 Gurova K. Can aggressive cancers be identified by the "aggressiveness" of their
551 chromatin? *Bioessays* 2022; 44: e2100212.
552
- 553 25 Ossovskaya VS, Mazo IA, Chernov MV, Chernova OB, Strezoska Z, Kondratov R *et al.*
554 Use of genetic suppressor elements to dissect distinct biological effects of separate p53
555 domains. *Proc Natl Acad Sci U S A* 1996; 93: 10309-10314.
556
- 557 26 Bates M, Jones SA, Zhuang X. Stochastic optical reconstruction microscopy (STORM): a
558 method for superresolution fluorescence imaging. *Cold Spring Harb Protoc* 2013; 2013:
559 498-520.
560
- 561 27 Shah S, Philipp LM, Giaimo S, Sebens S, Traulsen A, Raatz M. Understanding and
562 leveraging phenotypic plasticity during metastasis formation. *NPJ Syst Biol Appl* 2023; 9:
563 48.
564

565

566 **Figure Legends**

567 **Fig. 1. Measurement of nuclear fluorescence using non-confocal automated imaging. A.** Total
568 nuclear fluorescence is more accurately collected using non-confocal imaging. **B, C.** Distribution
569 of parameters of nuclear fluorescence in NDF and HT1080 cells in basal conditions. Cells were
570 fixed and stained with DAPI (**B**) or PI (**C**) 24 hours after plating.

571 **Figure 2. Optimization of the assessment of chromatin accessibility using fluorescent DNA**
572 **ligands.** Nuclear fluorescence was increased with a short-term treatment of NDF and HT1080 cells
573 with nucleosome-destabilizing compound CBL0137. **A, B.** Comparison of the performance of
574 different DNA dyes in the presence and absence of RNase A. **A.** Fold change in average nuclear
575 fluorescence per well relative to untreated cells. Data from two replicate wells with error bars
576 showing variability between replicates. A representative from > 3 similar experiments. **B.** Split
577 violin plots with quartiles showing mean nuclear fluorescence of cells treated with different
578 concentrations of CBL0137 for 60 min. Numbers above violins are p-values of the t-test comparing
579 treated cells to the untreated control stained either without RNase A (blue numbers) or with
580 RNase A (orange numbers). P-values were rounded to 4 decimal places. ns - p-value >0.05.
581 **C.** Split violin plots with quartiles showing mean nuclear fluorescence per cell fixed with
582 either 4% PFA or 100% methanol. Numbers on the plot are p-values of the t-
583 test comparing treated cells to untreated control fixed either with PFA (blue numbers) or methanol
584 (orange numbers). **D, E.** Fold change in average nuclear fluorescence per well of cells treated with
585 CBL0137 relative to untreated cells and stained in the presence of absence of RNase A. **D.** Cells
586 were stained with DAPI. **E.** Cells were stained with PI. Data from two replicate wells with error
587 bars showing variability between wells.

588 **Figure 3. Effect of epigenetic drugs on chromatin accessibility measured with PI.** NDF and
589 HT 1080 cells were treated with CBL0137 (500 nM), trichostatin A (TSA, 500 nM), panobinostat
590 (PNB, 20 nM), valproic acid (VA, 0.5 mM), SAHA (1000 nM), or JQ1 (1000 nM) for 24 hours
591 before fixation with PFA and staining with PI in the presence of RNase A. **A, B.** Number of
592 nuclei per well of NDF (**A**) or HT1080 (**B**) cells, untreated or treated with the drugs. Bars are mean
593 value of 4 replicate wells, error bars are SDV. Number above the bar is p-value of t-test comparing

594 each drug with the control untreated cells, rounded to 2 decimal points. **C, D.** Violin plots with
595 quartiles of distribution of PI nuclear fluorescence of cells in all replicate wells of NDF (**C**) or
596 HT1080 (**D**) cells treated with epigenetic drugs. Number above violin is p-value of t-test
597 comparing each drug with the control untreated cells, rounded to 4 decimal points. Pink and blue
598 transparent squares show position of quartiles 0.5 and 0.75 (pink), and 0.5 and 0.25 (blue) in
599 control untreated samples. **E, F.** Microscopic images of PI-stained wells from the plate of cells
600 treated with epigenetic drugs. The same exposition time was used for all images of NDF (**E**) and
601 HT1080 (**F**) cells.

602 **Figure 4. Dependence of chromatin accessibility of cell proliferation. A-D.** HT1080 cells were
603 incubated in the presence of EdU for 1 hour. After that cells were fixed and stained for EdU and
604 DAPI. **A.** Violin plots with quartiles of nuclear fluorescence of of EdU positive and negative cells.
605 Bleu squares correspond to the positions of quartiles (0.25, 0.5 and 0.75) in EdU negative cells. **B.**
606 Histogram of distribution of total nuclear fluorescence (Integral) in EdU negative and positive
607 cells. Blue squares show values of nuclear fluorescence used to select cells with DNA content
608 close to G1 or G2/M cells. **C, D.** Violin plots with quartiles showing mean nuclear fluorescence
609 of EdU positive and negative cells with DNA content close to G1 (**C**) or G2 /M (**D**). ns – p-value
610 > 0.05 . **E, F.** Comparison of mean nuclear fluorescence of NDF (**E**) or HT1080 (**F**) cells growing
611 in normal conditions or arrested with dense plating and medium with 1% FBS for 48 hours. Before
612 staining cells were treated with the indicated concentrations of CBL0137 for 60 minutes. Numbers
613 are p-values of t-test comparing growing and arrested cells at each concentration of CBL0137.


614

615 **Figure 5. Comparison of chromatin accessibility between normal, transformed and tumor**
616 **cells. A, B.** Split violin plots of mean nuclear fluorescence of NDF and HT1080 cells treated with

617 different concentrations of CBL0137 for 60 minutes and stained with DAPI (**A**) or PI (**B**). Numbers
618 are p-value of t-test comparing NDF and HT1080 cells. **C, D**. Violin plots with quartiles showing
619 mean nuclear fluorescence (DAPI) of two biological replicates of transformed NDF (**C**) or
620 MCF10A (**D**) cells (GR1, GR2) and control non transformed cells (EV). Numbers are p-values of
621 t-test comparing each of transformed variants (GR) with control non-transformed EV cells. **E, F**.
622 Comparison of nuclear fluorescence (PI) of mouse normal, transformed and tumor cells. **E**. Violin
623 plots with quartiles of mean nuclear fluorescence. Numbers above the lines show p-values of
624 ANOVA test comparing all groups. **F**. Distribution of total nuclear fluorescence. Numbers show
625 X-values of corresponding peaks on histograms. Dotted lines correspond to the positions of G1
626 peaks of normal MEF (red), transformed (blue) and tumor (green) cells.

627

628 **Figures**




629

630 **Fig. 1. Measurement of nuclear fluorescence using non-confocal automated imaging.** A. Total nuclear


631 fluorescence is more accurately collected using non-confocal imaging. B, C. Distribution of parameters of nuclear

632 fluorescence in NDF and HT1080 cells in basal conditions. Cells were fixed and stained with DAPI (B) or PI (C) 24


633 hours after plating.



635 **Figure 2. Optimization of the assessment of chromatin accessibility using fluorescent DNA ligands.** Nuclear
636 fluorescence was increased with a short-term treatment of NDF and HT1080 cells with nucleosome-destabilizing
637 compound CBL0137. **A, B.** Comparison of the performance of different DNA dyes in the presence and absence of
638 RNase A. **A.** Fold change in average nuclear fluorescence per well relative to untreated cells. Data from two replicate
639 wells with error bars showing variability between replicates. A representative from > 3 similar experiments. **B.** Split
640 violin plots with quartiles showing mean nuclear fluorescence of cells treated with different concentrations of
641 CBL0137 for 60 min. Numbers above violins are p-values of the t-test comparing treated cells to the untreated control
642 stained either without RNase A (blue numbers) or with RNase A (orange numbers). P-values were rounded to 4
643 decimal places. ns - p-value >0.05. **C.** Split violin plots with quartiles showing mean nuclear fluorescence per
644 cell fixed with either 4% PFA or 100% methanol. Numbers on the plot are p-values of the t-test comparing treated
645 cells to untreated control fixed either with PFA (blue numbers) or methanol (orange numbers). **D, E.** Fold change in
646 average nuclear fluorescence per well of cells treated with CBL0137 relative to untreated cells and stained in the
647 presence or absence of RNase A. **D.** Cells were stained with DAPI. **E.** Cells were stained with PI. Data from two
648 replicate wells with error bars showing variability between wells.
649




651 **Figure 3. Effect of epigenetic drugs on chromatin accessibility measured with PI.** NDF and HT 1080 cells were
652 treated with CBL0137 (500 nM) , trichostatin A (TSA, 500 nM), panobinostat (PNB, 20 nM), valproic acid (VA, 0.5
653 mM), SAHA (1000 nM), or JQ1 (1000 nM) for 24 hours before fixation with PFA and staining with PI in the presence
654 of RNase A. **A, B.** Number of nuclei per well of NDF (**A**) or HT1080 (**B**) cells, untreated or treated with the drugs.
655 Bars are mean value of 4 replicate wells, error bars are SDV. Number above the bar is p-value of t-test comparing
656 each drug with the control untreated cells, rounded to 2 decimal points. **C, D.** Violin plots with quartiles of distribution
657 of PI nuclear fluorescence of cells in all replicate wells of NDF (**C**) or HT1080 (**D**) cells treated with epigenetic drugs.
658 Number above violin is p-value of t-test comparing each drug with the control untreated cells, rounded to 4 decimal
659 points. Pink and blue transparent squares show position of quartiles 0.5 and 0.75 (pink), and 0.5 and 0.25 (blue) in
660 control untreated samples. **E, F.** Microscopic images of PI-stained wells from the plate of cells treated with epigenetic
661 drugs. The same exposition time was used for all images of NDF (**E**) and HT1080 (**F**) cells.
662



663

664 **Figure 4. Dependence of chromatin accessibility of cell proliferation.** A-D. HT1080 cells were incubated in the
 665 presence of EdU for 1 hour. After that cells were fixed and stained for EdU and DAPI. A. Violin plots with quartiles
 666 of nuclear fluorescence of of EdU positive and negative cells. Bleu squares correspond to the positions of quartiles
 667 (0.25, 0.5 and 0.75) in EdU negative cells. B. Histogram of distribution of total nuclear fluorescence (Integral) in EdU
 668 negative and positive cells. Blue squares show values of nuclear fluorescence used to select cells with DNA content
 669 close to G1 or G2/M cells. C, D. Violin plots with quartiles showing mean nuclear fluorescence of EdU positive and

670 negative cells with DNA content close to G1 (**C**) or G2 /M (**D**). ns – p-value > 0.05. **E, F**. Comparison of mean nuclear
671 fluorescence of NDF (**E**) or HT1080 (**F**) cells growing in normal conditions or arrested with dense plating and medium
672 with 1% FBS for 48 hours. Before staining cells were treated with the indicated concentrations of CBL0137 for 60
673 minutes. Numbers are p-values of t-test comparing growing and arrested cells at each concentration of CBL0137.



675 **Figure 5. Comparison of chromatin accessibility between normal, transformed and tumor cells. A, B.** Split violin
676 plots of mean nuclear fluorescence of NDF and HT1080 cells treated with different concentrations of CBL0137 for
677 60 minutes and stained with DAPI (**A**) or PI (**B**). Numbers are p-value of t-test comparing NDF and HT1080 cells. **C,**
678 **D.** Violin plots with quartiles showing mean nuclear fluorescence (DAPI) of two biological replicates of transformed
679 NDF (**C**) or MCF10A (**D**) cells (GR1, GR2) and control non transformed cells (EV). Numbers are p-values of t-test
680 comparing each of transformed variants (GR) with control non-transformed EV cells. **E, F.** Comparison of nuclear
681 fluorescence (PI) of mouse normal, transformed and tumor cells. **E.** Violin plots with quartiles of mean nuclear
682 fluorescence. Numbers above the lines show p-values of ANOVA test comparing all groups. **F.** Distribution of total
683 nuclear fluorescence. Numbers show X-values of corresponding peaks on histograms. Dotted lines correspond to the
684 positions of G1 peaks of normal MEF (red), transformed (blue) and tumor (green) cells.

685

686

687

688

689

690

691

692

693

694

695

696

697

698